Polycaprolactone microspheres as carriers for dry powder inhalers: Effect of surface coating on aerosolization of salbutamol sulfate

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 733-745

  Tuli, Rinku A ^a   Dargaville, Tim R ^a   George, Graeme A ^a   Islam, Nazrul ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Aerosols; Biodegradable polymers; Microparticles; Polymeric drug carrier; Pulmonary drug delivery

Indexed keywords

DRUG CARRIER; LEUCINE; MAGNESIUM STEARATE; MICROSPHERE; POLYCAPROLACTONE; POLYVINYL ALCOHOL; SALBUTAMOL SULFATE;

ADHESION; AEROSOL; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; IN VITRO STUDY; PARTICLE SIZE; POWDER INHALER; SCANNING ELECTRON MICROSCOPY;

EID: 84455179008     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22777     Document Type: Article

References (53)

1. Chan HK. 2006. Dry powder aerosol delivery systems: Current and future research directions. J Aerosol Med 19(1):21-27.
2. Prime D, Atkins PJ, Slater A, Sumby B. 1997. Review of dry powder inhalers. Adv Drug Deliv Rev 26(1):51-58.
3. Hersey JA. 1974. Letter: Powder mixing by frictional pressure: Specific example of use of ordered mixing. J Pharm Sci 63(12):1960-1961.
4. Hickey AJ, Concessio NM. 1997. Descriptors of irregular particle morphology and powder properties. Adv Drug Deliv Rev 26(1):29-40.
5. Young PM, Cocconi D, Colombo P, Bettini R, Price R, Steele DF, Tobyn MJ. 2002. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing". J Pharm Pharmacol 54:1339-1344.
6. Islam N, Stewart P, Larson I, Hartley P. 2005. Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy. J Pharm Sci 94(7):1500-1511.
7. Begat P, Price R, Harris H, Morton D, Staniforth J. 2005. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA 23:109-121.
8. Zeng XM, Martin GP, Marriott C, Pritchard J. 2000. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 200(1):93-106.
9. French DL, Edwards DA, Niven RW. 1996. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 27(5):769-783.
10. Steckel H, Müller BW. 1997. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 154(1):31-37.
11. Steckel H, Muller BW. 1997. In vitro evaluation of dry powder inhalers I: Drug deposition of commonly used devices. Int J Pharm 154(1):19-29.
12. Malcolmson RJ, Embleton JK. 1998. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today 1(9):394-398.
13. Concessio NM, VanOort MM, Knowles MR, Hickey AJ. 1999. Pharmaceutical dry powder aerosols: Correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm Res 16(6):828-834.
14. Taylor MK, Ginsburg J, Hickey A, Gheyas F. 2000. Composite method to quantify powder flow as a screening method in early tablet or capsule formulation development. AAPS PharmSciTech 1(3):E18.
15. Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, Mulder T, McLean R, Langridge J, Papadopoulos D. 2007. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sci 96(5):1302-1319.
16. Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, Mulder T, McLean R, Langridge J, Papadopoulos D. 2007. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci 96(5):1282-1301.
17. Larhrib H, Zeng XM, Martin GP, Marriott C, Pritchard J. 1999. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int J Pharm 191(1):1-14.
18. Steckel H, Muller BW. 1997. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition. Int J Pharm 154(1):31-37.
19. Karhu M, Kuikka J, Kauppinen T, Bergström K, Vidgren M. 2000. Pulmonary deposition of lactose carriers used in inhalation powders. Int J Pharm 196(1):95-103.
20. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. 1998. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm 172(1-2):179-188.
21. Ganderton D, Morton DAV, Lucas P. 2000. Improvements in or relating to powders. International Patent WO/00/33811.
22. Lucas P, Anderson K, Potter UJ, Staniforth JN. 1999. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm Res 16(10):1643-1647.
23. Staniforth JN. 1995. Performance-modifying influences in dry powder inhalation systems. Aerosol Sci Technol 22(4):346-353.
24. Staniforth JN. 1996. Carrier particles for use in dry powder inhalers. International Patent WO/96/23485.
25. Staniforth JN. 1997. Improvements in or relating to powders for use in dry powder inhalers. International Patent WO/97/03649.
26. Chew NY, Shekunov BY, Tong HH, Chow AH, Savage C, Wu J, Chan HK. 2005. Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci 94(10):2289-2300.
27. Yue B, Yang J, Wang Y, Huang CY, Dave R, Pfeffer R. 2004. Particle encapsulation with polymers via in situ polymerization in supercritical CO2. Powder Technol 146(1-2):32-45.
28. Lahde A, Raula J, Kauppinen EI. 2008. Production of l-leucine nanoparticles under various conditions using an aerosol flow reactor method. J Nanomater 2008:1-9.
29. Raula J, Kuivanen A, Lahde A, Kauppinen EI. 2008. Gas-phase synthesis of l-leucine-coated micrometer-sized salbutamol sulphate and sodium chloride particles. Powder Technol 187(3):289-297.
30. Tee SK, Marriott C, Zeng XM, Martin GP. 2000. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm 208(1-2):111-123.
31. Jaspart S, Bertholet P, Piel G, Dogné JM, Delattre L, Evrard B. 2007. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 65(1):47-56.
32. Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, Evrard B. 2004. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech 5(2):27.
33. Katainen J, Paajanen M, Ahtola E, Pore V, Lahtinen J. 2006. Adhesion as an interplay between particle size and surface roughness. J Colloid Interface Sci 304(2):524-529.
34. Li Q, Rudolph V, Peukert W. 2006. London-van der Waals adhesiveness of rough particles. Powder Technol 161(3):248-255.
35. Podczeck F. 1999. The influence of particle size distribution and surface roughness of carrier particles on the in vitro properties of dry powder inhalations. Aerosol Sci Technol 31(4):301-321.
36. Emami J, Hamishehkar H, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, Mirzadeh H, Fakhari A, Nokhodchi A. 2009. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J Microencapsul 26(1):1-8.
37. Kumari A, Yadav SK, Yadav SC. 2010. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75(1):1-18.
38. Shenoy DB, Amiji MM. 2005. Poly(ethylene oxide)-modified poly([var epsilon]-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 293(1-2):261-270.
39. Kim SY, Lee YM. 2001. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly([var epsilon]-caprolactone) as novel anticancer drug carriers. Biomaterials 22(13):1697-1704.
40. Prabu P, Chaudhari AA, Dharmaraj N, Khil MS, Park SY, Kim HY. 2009. Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug. J Biomed Mater Res A 90(4):1128-1136.
41. Zheng D, Li X, Xu H, Lu X, Hu Y, Fan W. 2009. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim Biophys Sin 41(7):578-587.
42. Damgé C, Maincent P, Ubrich N. 2007. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 117(2):163-170.
43. Shah LK, Amiji MM. 2006. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res 23(11):2638-2645.
44. Espuelas MS, Legrand P, Loiseau PM, Bories C, Barratt G, Irache JM. 2002. In vitro antileishmanial activity of amphotericin B loaded in poly(ε-caprolactone) nanospheres. J Drug Target 10(8):593-599.
45. Kho K, Cheow WS, Lie RH, Hadinoto K. 2010. Aqueous re-dispersibility of spray-dried antibiotic-loaded polycaprolactone nanoparticle aggregates for inhaled anti-biofilm therapy. Powder Technol 203(3):432-439.
46. Wang S, Guo S. 2008. Disodium norcantharidate-loaded poly(ε-caprolactone) microspheres: II. Modification of morphology and release behavior. Int J Pharm 353(1-2):15-20.
47. Alway B, Sangchantra R, Stewart PJ. 1996. Modelling the dissolution of diazepam in lactose interactive mixtures. Int J Pharm 130(2):213-224.
48. Ducker WA, Senden TJ, Pashley RM. 1991. Direct measurement of colloidal forces using an atomic force microscope. Nature 353(6341):239-241.
49. Larson I, Drummond CJ, Chan DYC, Grieser F. 1993. Direct force measurements between titanium dioxide surfaces. J Am Chem Soc 115(25):11885-11890.
50. Hutter J, Bechhoefer J. 1993. Calibration of atomic force microscope tips. Rev Sci Instrum 64:1868-1873.
51. Senden T, Ducker W. 1994. Experimental determination of spring constants in atomic force microscopy. Langmuir 10(4):1003-1004.
52. Atanasoska L, Cammarata V, Stallman BJ, Kwan WSV, Miller LL. 1992. Langmuir-Blodgett films of rigid rod oligoimides on gold: An X-ray photoelectron spectroscopy study. Surf Interface Anal 18(2):163-172.
53. Andrade JD. 1985. X-Ray photoelectron spectroscopy (XPS). In Surface and interfacial aspects of biomedical polymers; Andrade JD, Ed. New York: Plenum Publishing Corporation, p 181.